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PPAR ligand attenuates PDGF-induced mesangial cell prolif- The interaction of proliferative and antiproliferative
eration: Role of MAP kinase. signals leads to repopulation of the mesangium and tissue
Background. Mesangial proliferation is a key feature in the remodeling. In animal models (e.g., anti-Thy-1 nephritis)
pathogenesis of a number of renal diseases and can be experi-
and in humans, platelet-derived growth factor (PDGF)mentally induced by the mitogen platelet-derived growth factor
plays a major role in the pathogenesis of mesangioproli-(PDGF). Mitogen-activated protein kinase (MAPK) signaling
ferative glomerular disorders [1]. It has been observedplays a key role in mesangial cell proliferation. In the present
study we examined whether peroxisome proliferator-activated that PDGF is released during immune injury. If the injury
receptor gamma (PPAR) activators/ligands, thiazolidinedi- is transient or short-lived there is eventual restoration of
ones such as ciglitazone, troglitazone, and rosiglitazone, can normal glomerular morphology, whereas repeated treat-
inhibit cell proliferation by modulating individual steps in the
ment with anti-Thy-1 antibody and concomitant PDGFMAPK pathway.
release result in progressive sclerosis. Thus, glomerularMethods. Mouse mesangial cells were made quiescent and
function is preserved in many patients with immuno-proliferation was measured following the application of PDGF.
Using ciglitazone as the model compound, the mechanism of globulin A (IgA) nephropathy, while other patients with
the antiproliferative effect of PPAR activators on MAPK sustained immune stimulation develop proliferative and
and specific cell cycle regulatory proteins were examined by sclerosing lesions with eventual renal failure [1]. In theWestern blot analysis and transfection studies.
anti-Thy-1 nephritis model, mediators of proliferative mes-Results. Ciglitazone inhibited PDGF-induced mesangial cell
angial injury, PDGF and fibroblast growth factor (FGF),proliferation in a dose-dependent manner (1 to 20 mol/L).
play a major role in complement-dependent injury toThe inhibitory effect was blocked by a peroxisome proliferator-
activated receptor element (PPRE) decoy oligonucleotide, in- the mesangium, causing nondamaged mesangial cells to
dicating that the observed effect of ciglitazone was via PPAR migrate from the extramesangial region and proliferate,
activation. Ciglitazone (1 to 20 mol/L) did not affect extracel- giving rise to a mesangioproliferative nephritis [1–3].lular signal-regulated protein kinase (ERK) activation but in-
The signaling pathway activated in PDGF-stimulatedhibited the activation of serum response element (SRE) by
mitogenesis in the mitogen-activated protein (MAP) kinase85 6% (P 0.01). This effect was associated with a reduction
in c-fos expression (80  9%, P  0.01). Ciglitazone (1, 10, pathway involves Ras→Raf→MEK→Erk→Elk-1→SRE→
and 20 mol/L) also inhibited cyclin D1 expression by 37  c-fos (Fig. 1). Extracellular signal-regulated protein ki-
8%, 79  15%, and 87  12%, respectively (P  0.001 to nase (ERK) directly activates the transcription factor
0.001), and p21 expression by 45  6% (P  0.01), 61  10% ELK-1, which binds to the serum response element(P 0.001), and 72 8% (P 0.001), respectively. Ciglitazone
(SRE), facilitating induction of c-fos [4]. Fibroblasts de-inhibited PDGF-mediated up-regulation of p27. In addition,
ficient in c-fos exhibit reduced proliferation [5] and arethe antiproliferative effect of ciglitazone was potentiated by
partially defective in reentering the cell cycle [6]. Tran-PD98059, a mitogen-activated protein (MAP) kinase kinase
(MEK) inhibitor that acts at a step upstream from ERK. scriptional activation of the c-fos gene by PDGF is stimu-
Conclusion. These data indicate that PPAR activation may lated, at least in part, through the interaction of transcrip-
inhibit mesangial growth directly by affecting MAPK and cell tion factors with an SRE located in the c-fos 5-flanking
cycle regulatory proteins. Furthermore, a MAP kinase inhibitor
DNA [7, 8]. C-fos and its heterodimeric partner, c-juncan potentiate the antiproliferative effect.
(AP-1 complex), promote cell proliferation by transacti-
vation of cyclin D1, a key protein promoting the cell
Key words: AP-1, decoy oligonucleotide, ciglitazone, cyclin D1. cycle [9]. Cyclin D1 gene has been shown to harbor two
AP-1 response elements in the promoter region [10], aReceived for publication April 26, 2002
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Fig. 1. Effect of ciglitazone on platelet-derived
growth factor (PDGF)-mediated activation of
the mitogen-activated protein kinase (MAPK).
The signal transduction steps linking the
PDGF receptor with extracellular signal-regu-
lated protein kinase (ERK) in mesangial cells
is shown in the schematics. PDGF activates
ERK by phosphorylation. Once activated,
ERK translocates to the nucleus and phos-
phorylates the transcription factor ELK-1.
Phosphorylated ELK-1 and serum response
factor (SRF) bind to the serum response ele-
ment (SRE) on the c-fos promoter, leading to
c-fos transcription. c-fos dimerizes with c-jun
to form the AP-1 complex, which transacti-
vates target genes such as cyclin D1 and stimu-
lating G1 to S phase progression in the cell
cycle. Ciglitazone blocks cell cycle progression
by inhibiting SRE and cylin D1 formation.
proliferator-activated receptor gamma (PPAR) ligands. METHODS
PPAR is a member of the nuclear hormone receptor Cell culture
superfamily originally shown to play a critical role in Mouse mesangial cells were obtained from American
adipocyte differentiation and glucose homeostasis and Type Culture Collection, Manassas, VA, USA and were
has been implicated as a regulator of cellular prolifera- grown in Ham’s F12 and Dulbecco’s modified Eagle’s
tion and inflammatory responses in the kidney [11]. medium (DMEM) with 5% fetal bovine serum (FBS).
PPAR receptors are widely distributed in human and Cells were plated in either 24-well plates or 35 mm plates
animal tissue, including rat mesangial cells [12] and prox- and grown to60% confluence. Cells were made quiescent
imal tubular cells [13]. The TZD analog troglitazone by serum starving them for 48 hours and then treating with
stops the progression of glomerulosclerosis by pre- 20 ng/mL of PDGF for 24 hours. In some experiments,
venting mesangial cell expansion [14]. cells were pretreated with different concentrations (1 to
In the present study we sought to investigate the effect 20 mol/L) of ciglitazone for 4 hours before the addition
of ciglitazone, another TZD analog, on mesangial cell of PDGF. Cell viability was measured before and after
proliferation in the MAP kinase pathway. In addition, treatment with ciglitazone by 3-[4,5]dimethylthiazol-2,5-
we investigated the effects of ciglitazone in combination diphenyltetrazolium bromide (MTT).
with an ERK inhibitor, PD98059, on cell proliferation.
Measurement of cell proliferationThe results indicate that ciglitazone reduces mesangial
cell proliferation by inhibiting pathways downstream of Cell proliferation was measured by an Alamar Blue
ERK activation. This inhibitory effect is exerted through (Biosource International, Camarillo, CA, USA) based
a PPAR-dependent pathway. This is the first report dem- assay as described by Ahmed et al [15] and deFries and
onstrating that concurrent administration of upstream and Mitshuhashi [16]. Mesangial cells were plated at 5.0 
downstream inhibitors of MAP kinase pathway can po- 104 cells in 24-well plates. After serum starvation for 48
hours the cells were treated with PDGF (20 ng/mL) intentiate an antiproliferative effect on mesangial cells.
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the presence or absence of ciglitazone (1 to 20 mol/L) strumentation, Eugene, OR, USA) and imaged with a
for 24 hours. Alamar Blue was added to all the wells for setup consisting of a cooled CCD camera (Imago T.I.L.L.
4 hours. The final concentration of the dye in each well Photonics; Applied Scientific Instrumentation) attached
was 10%. Proliferation was evaluated by microplate spec- to an image intensifier (VS4-1845; Videoscope, Washing-
troflurometer interfaced to an IBM personal computer ton, DC, USA), an epifluorescent light source (T.I.L.L.
(Molecular Devices, Sunnyvale, CA, USA) using excita- Photonics Polychrome IV; T.I.L.L. Photonics GmbH,
tion wavelength of 530 nm and emission of 560 nm. Gra¨feling, Germany), a 515 nm dichroic beam splitter
(Omega Optical, Applied Scientific Instrumentation),
Measurement of cell viability and a 535 nm emission filter (20 nm band pass; Omega
The effect of ciglitazone on mesangial cell viability Optical). The cells were alternatively excited at 490 and
was assayed using the Cell Titer 96 cytotoxicity assay 440 nm and imaged at 10-second intervals. Small regions
protocol (Promega, Madison, WI, USA). The Cell Titer of interest (ROIs) in the mesangial cells were chosen in
96 assay is based on the cellular conversion of a tetrazo- which the changes in fluorescent intensity ratio F490/
lium salt into a formazan product, which can be easily F440 were analyzed using TILLvisION v3.1 imaging soft-
detected at a wavelength of 600 nm. Mesangial cells were ware (T.I.L.L.). In a typical experiment the fluorescent
plated in 96-well plates. Twenty-four hours later they intensity ratio measurement contained at least 25 to 30
were serum starved for 48 hours. To minimize serum- ROIs. The changes in pHi were calibrated by high-K
mediated proliferation and to prevent cell death, the calibrating solution containing 10 mol/L nigericin ad-
mesangial cells were supplemented with 0.5% serum- justed to pHs between 6.5 and 8.0. NHE activity was
containing media at the end of 48 hours. Two hours later estimated in terms of both steady-state pHi values and
ciglitazone was added to the cells and the control cells the rate of proton efflux. The mesangial cells were acid
received dimethyl sulfoxide (DMSO) (vehicle). At the loaded by transient 150-second exposures to 15 mmol/L
end of 24 hours, 15 L Promega premixed dye solution NH4Cl followed by washout with Na free buffer. Rein-was added to the cells and incubated at 37C for 4 hours troducing external Na induced recovery of pHi afterin a CO2 incubator. After 4 hours the 100 L solubiliza- acid loading. The rate of pH recovery (	pHi/min) wastion/stop solution was added and the plate was shaken calculated as the derivative of the exponential fit of pHifor one hour. At the end of the hour the absorbance versus time.
was recorded at 600 nm using a plate reader (Bio-Tek
Instruments, Winooski, VT, USA). Transfection of pPPRE(AOx)3-Luc and PPAR
decoy oligonucleotidesTransfection of serum response element (SRE)
PPRE decoy oligonucleotide contained two tandemcontaining reporter vector
repeats of the consensus DR1 (AGGTCAAAGGTCA),Mesangial cells were transiently transfected with 200 ng
separated by two nucleotides as follows: GCAGGTCAplasmid containing serum response element with se-
AAGGTCATTAGGT CAAAGGTCAGC. The scram-cretory alkaline phosphatase reporter gene (SRE-SEAP)
bled oligonucleotide used in this study was ATATTGpurchased from Clontech (BD Biosciences Clontech,
CCGTACCTGACTTAGCCCTAT. The decoy or thePalo Alto, CA, USA). Transfections were performed
scrambled oligonucleotide was annealed to its respectiveusing Effectene (Promega) according to the manufactur-
complementary sequence in Tris-ethylenediaminetetra-er’s instruction. Renilla luciferase plasmid with a thymi-
acetic acid (EDTA) buffer (pH 7.4). Mesangial cells plateddine kinase promoter (pRL-TK) was used as an internal
in 24-well plates were cotransfected with 200 ng of PPARcontrol and was transfected along with SRE-SEAP.
reporter vector, pPPRE(AOx)3-Luc, (kindly donated bySEAP activity was measured using Great EscaPe chemi-
Dr. C. Glass and Dr. M. Ricotte), renilla luciferase, andluminescence detection kit (Clontech Laboratories) and
decoy or scrambled oligonucleotide. The control cells re-normalized to renilla luciferase activity. The results were
ceived empty vector. Twenty-four hours after transfec-expressed as relative luminesence units (RLU).
tion the cells were stimulated with 10 mol/L of ciglita-
Measurement of sodium hydrogen exchanger zone. Eighteen hours later the cells were harvested for
(NHE) activity luciferase activity and normalized to renilla luciferase.
The results were expressed as relative luminescence unitsSodium hydrogen exchanger (NHE) activity was mea-
(RLU).sured as described by Lyall et al [17]. Briefly, mesangial
For proliferation experiments cells cultured in 24-wellcells were intermittently perfused with Ringer’s solution
plates were transfected with either 200 nmol/L of eithercontaining 25 mol/L of the pH-sensitive fluoroprobe
decoy or scrambled oligonucleotides (Life Technologies,BCECF-AM (Molecular Probes, Eugene, OR, USA) for
Invitrogen, Carlsbad, CA, USA) using oligofectamine as60 minutes. The mesangial cells were visualized through
per the manufacturer’s instruction. After 4 hours the cellsa 40 objective with a Zeiss Axioskop 2 plus upright
fluorescence microscope (Zeiss, Applied Scientific In- were treated with 20 ng/mL of PDGF in the presence or
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Fig. 3. Effect of ciglitazone on the pHi recovery from NH4Cl prepulse.
Cells were perfused with control Ringer’s solution containing 150 mmol
NaCl (pH 7.4). Temporal changes in pHi were monitored following a
Fig. 2. Effect of ciglitazone on platelet-derived growth factor (PDGF)- short NH4Cl pulse (15 mmol NH4Cl replaced 15 mmol NaCl in the
stimulated cell proliferation. Mesangial cells were made quiescent by Ringer’s solution). The bar at the top represents the time period for
incubating the cells for 48 hours in serum-free media. At the end of 48 the NH4Cl pulse. Values are presented as mean  SD. N 
 35.
hours, serum- free media was replaced with 0.5% serum-containing
media and the cells were exposed to PDGF (20 ng/mL) in presence or
absence of 1, 10, and 20 mol/L of ciglitazone. Ciglitazone was added
macia, Amersham Biosciences, Piscataway, NJ, USA).4 hours prior to PDGF. Cell proliferation was measured using Alamar
Blue by a spectrofluorometric method. Data represent mean  SD All antibodies were purchased from Santa Cruz Biotech-
of six experiments (each in duplicate). Ciglitazone dose dependently nology (Santa Cruz, CA, USA).
inhibited PDGF-stimulated cell proliferation. P  0.01; P  0.05 less
than PDGF.
RESULTS
absence of 10 mol/L ciglitazone. Cell proliferation was Effect of Ciglitazone on cell proliferation
measured using Alamar Blue as previously described. Treatment of serum starved mesangial cells with
PDGF (20 ng/mL) for 24 hours significantly increasedWestern blot analysis
proliferation (↑190  9%, P  0.05), measured by theTotal mesangial cell proteins were extracted according
incorporation of Alamar Blue dye (Fig. 2). Pretreatmentto the method described by Lang et al [18]. Unless men-
with ciglitazone, troglitazone, and rosiglitazone for 4tioned otherwise, 50g total cell proteins were separated
hours significantly inhibited PDGF-induced prolifera-by sodium dodecyl sulfate polyacrylamide gel electro-
tion. The antiproliferative effect of ciglitazone was con-phoresis (SDS-PAGE) (8% to 16% gradient gel) and
centration-dependent, with 33  8% (P  0.05), 58 electroblotted to nitrocellulose filters (Millipore, Bed-
8% (P  0.01), and 67  9% (P  0.01) inhibitionford, MA, USA). Membranes were blocked for 1 hour
at 1 mol/L, 10 mol/L, and 20 mol/L of ciglitazone,with Tris-buffered saline (TBS) containing 5% nonfat
respectively (Fig. 2). Although ciglitazone is a classicdried milk (Bio-Rad, Hercules, CA, USA) and then incu-
TZD, it is less potent than either rosiglitazone or troglita-bated with the antibodies to pERK (1:10,000), c-fos
zone. The antiproliferative potency of the TZD tested(1:5000), cyclin D (1:5000), p21, and p27 (1:1000) in TBS
were as follows: troglitazonerosiglitazoneciglitazone.containing 5% nonfat dried milk for 18 hours at 4C.
In animal studies it has been shown that troglitazoneThe membranes were washed three times with TBS and
halts mesangial expansion [14], and it has been demon-incubated with horseradish peroxidase (HRP)-conjugated
strated that troglitazone affects NHE and spontaneoussecondary antibody (1:10,000) for 2 hours at room tem-
acidosis [19]. Therefore we evaluated the role of ciglita-perature, and then washed three times with TBS con-
zone on NHE activity in cultured mesangial cells. In thetaining 0.05% Tween 20. The blots were reprobed with
presence and absence of ciglitazone the NHE activity wasmouse monoclonal actin antibody to ensure equal load-
0.06 .01 and 0.06  .02 	pH/min, respectively, and thising. Proteins were visualized using the enhanced chemi-
luminescence (ECL) detection system (Amersham Phar- difference was not statistically significant (Fig. 3). PDGF
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Fig. 4. Ciglitazone does not affect mesangial cell viability. Mesangial
cells were made quiescent by incubating the cells for 48 hours in serum-
free media. At the end of 48 hours serum-free media was replaced
with 0.5% serum. The cells were treated with 1, 10, and 20 mol/L of
ciglitazone for 24 hours, at which time a 3-[4,5]dimethylthiazol-2,5-
diphenyltetrazolium bromide (MTT) assay was performed. The results
are mean  SD of 5 experiments.
Fig. 5. Effect of ciglitazone on platelet-derived growth factor (PDGF)-activated NHE (0.1  .01 	pH/min, P  0.001) and
stimulated extracellular signal-regulated protein kinase (ERK) activa-troglitazone significantly decreased NHE (0.072  0.01 tion. Mesangial cells were made quiescent by incubating the cells for
	pH/min, P  0.05). Unlike troglitazone, ciglitazone did 48 hours in serum-free media. At the end of 48 hours, serum-free media
was replaced with 0.5% serum-containing media and the cells werenot significantly change PDGF-induced NHE activity
exposed to PDGF (20 ng/mL) in presence or absence of 1, 10, and 20(0.09  .02 	pH/min). These results suggest that ciglita- mol/L of ciglitazone (Cig). Ciglitazone was added 4 hours prior to the
zone, like rosiglitazone [20], does not affect NHE activ- addition of PDGF. After 24 hours, total cell extracts (20 g) were
assayed by Western blotting using phosphorylated ERK antibody. Eachity. Although rosiglitazone is a more potent PPAR acti-
autoradiogram is representative of 5 separate experiments. ERK activity
vator than troglitazone and ciglitazone, the superior was analyzed by scanning the autoradiograms and was expressed as
fold change from control. The control value was considered to be 100%.antiproliferative effect of troglitazone may be mediated
The results are mean  SD of 5 experiments.by both PPAR activation and its effect on NHE.
To confirm that ciglitazone was not cytotoxic to mes-
angial cells, cell viability was assessed using MTT, which
measures mitochondrial function (Fig. 4). Since mito- twofold (P  0.05) (Fig. 5). Pretreatment of cells with
chondrial respiration is also an indicator of cell growth, 1 to 20 mol/L of ciglitazone had no significant effect
the mesangial cells were grown in an optimal serum on ERK phosphorylation, indicating that ciglitazone may
concentration of 0.5%. At this concentration mesangial be affecting steps downstream from ERK.
cell proliferation was minimal. The data in Figure 3 show
that ciglitazone (1 to 20 mol/L) has no effect on cell Effect of ciglitazone on serum response element
(SRE) mediated gene expressionviability as indicated by equivalent mitochondrial activ-
ity in control and ciglitazone-treated mesangial cells. Since ciglitazone could affect the PDGF-stimulated
MAP kinase pathway downstream from ERK activation,
Effect of ciglitazone on ERK phosphorylation we investigated the effect of ciglitazone on PDGF-induced
ERK activation plays a major role in PDGF-induced SRE-mediated gene expression. SRE-mediated gene ex-
proliferation of mesangial cells [21]. Inhibition of cell pression was measured in mesangial cells using SRE re-
proliferation by ciglitazone raised the possibility that the porter vector SRE-SEAP (Fig. 6). An almost fourfold
effects of ciglitazone may be mediated via inhibition of increase in SEAP activity was observed with 20 ng/mL
ERK phosphorylation. ERK phosphorylation was mea- PDGF. As shown in Figure 6, pretreatment of cells with
sured by Western blot analysis using antibodies specific ciglitazone inhibited PDGF-induced SEAP activity in a
to phosphorylated ERK. Treatment of cells with PDGF concentration-dependent manner, suggesting that PDGF
attenuates SRE mediated gene expression (↓48  9%(20 ng/mL) for 4 hours increased ERK phosphorylation
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Fig. 6. Ciglitazone inhibits platelet-derived growth factor (PDGF)-
stimulated serum response element (SRE) activity. Mesangial cells were
transiently transfected with SRE-SEAP (200 ng DNA), a plasmid-
containing SRE with secretory alkaline phosphatase reporter gene.
pRL-TK, Renilla luciferase plasmid with a thymidine kinase promoter,
was used to control for transfection efficiency. PDGF (20 ng/mL) in
presence or absence of 1, 10, and 20 mol/L ciglitazone (Cig) in 0.5%
serum-containing media. SEAP activity was measured by luminometer
and indexed to Renilla luciferase activity. Data are expressed as indexed
relative luminesence units (RLU). The results are mean  SD of 5
experiments. *P  0.01 and †P  0.05 less than PDGF.
Fig. 7. Ciglitazone inhibits platelet-derived growth factor (PDGF)-
stimulated c-fos expression. Mesangial cells were gown to 50 conflu-
ence and made quiescent by 48-hour incubation in serum-free media.
At the end of 48 hours, serum-free media was replaced with 0.5%P  0.05, ↓76  7%, P  0.01, and ↓85  6, P  0.01 at
serum-containing media and the cells were exposed to PDGF (20 ng/1 mol/L, 10 mol/L, and 20 mol/L, respectively). mL) in presence or absence of 1, 10, and 20 mol/L ciglitazone (Cig).
Ciglitazone was added 4 hours prior to the addition of PDGF. After
24 hours, the cells were lysed in ice and total proteins were extracted.Effect of ciglitazone on c-fos expression
Total cell extracts (50 g protein) were separated by sodium dodecyl
SRE is located in the 5 flanking region of the c-fos sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in 8-16% gels.
c-fos protein levels were analyzed by Western blotting using c-fos anti-gene and regulates c-fos expression. To see if decreased
body (1:5000) and standardized using actin. The autoradiogram at theSRE mediated gene expression resulted in decreased
top is representative of 5 experiments. c-fos and actin protein were
c-fos expression, cells were treated with PDGF in the analyzed by scanning the autoradiograms. The ratio of c-fos and actin
was expressed as fold change from the control. The control value waspresence and absence of ciglitazone and c-fos expression
considered to be 100%. The results are expressed as mean  SD. *P was measured by Western blot analysis (Fig. 7). PDGF
0.01 and †P  0.05 less than PDGF.
increased c-fos expression by 5.5-fold. As shown in Fig-
ure 7, c-fos expression was dose dependently inhibited
in mesangial cells pretreated with 1, 10, and 20 mol/L ated attenuation of c-fos expression we monitored the
ciglitazone (↓28 8%, P 0.05, ↓66 11%, P 0.01and expression of cyclin D1 in mesangial cells. Treatment of
↓80  9% P  0.01 by 1, 10, and 20 mol/L ciglitazone, serum starved mesangial cells with PDGF (20 ng/mL)
respectively). Taken together with the effects of ciglita- for 24 hours markedly up-regulated the protein levels of
zone on SRE reporter activity these results demonstrate cyclin D1 (Fig. 8). As shown in Figure 8, pretreatment
that ciglitazone attenuates SRE-mediated c-fos expression. with ciglitazone for 4 hours significantly inhibited PDGF-
induced cyclin D1 expression (↓37  8%, P  0.01, ↓79 
Effect of ciglitazone on cyclin D1 expression 15%, P  0.001, and ↓87  12%, P  0.001 at 1 mol/L,
Expression of cyclin D1 acts in G1 phase to promote 10 mol/L, and 20 mol/L of ciglitazone, respectively).
progression through the cell cycle. Increased expression
Effect of ciglitazone on p21 and p27 expressionof cyclin D1 is regulated by AP-1, a heterodimeric tran-
scription factor containing c-fos and c-jun proteins [10]. Expression of cyclin D is also regulated by the cyclin
D-dependent kinase (CDK) inhibitor p27kip1 and p21Cip1.To examine the downstream effects of ciglitazone-medi-
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cyclin D1 [22, 23]. We investigated the effect of ciglita-
zone on p21 expression after 24-hour PDGF stimulation.
As shown in Figure 9B, Western blot analysis showed
low levels of p21 expression in quiescent mesangial cells,
but PDGF increased p21 expression twofold. The cells
treated with 1, 10, and 20 mol/L of ciglitazone signifi-
cantly decreased PDGF-induced p21 expression by 45 
6% (P  0.01), 61  10% (P  0.001), and 72  8%
(P  0.001), respectively. Taken together with the effect
of ciglitazone on cyclin D1 expression, these results dem-
onstrate that ciglitazone attenuates proliferation by in-
creasing cyclin D1 expression as well as affecting the
levels of CDK inhibitor p21 and p27.
Role of PPAR in antiproliferative effect
of ciglitazone
PPAR agonists such as ciglitazone and other TZDs
can inhibit cell proliferation. However, there are recent
reports that the pharmacologic effect of these drugs can
be independent of PPAR activation [24–26]. To deter-
mine the mechanism involved in the antiproliferative
effect of ciglitazone, mesangial cells were cotransfected
with a PPAR reporter vector and PPRE decoy oligonu-
cleotide/scrambled oligonucleotide. PPRE-driven lucif-
erase activity was monitored and normalized to renilla
luciferase. Compared to cells transfected with vector
Fig. 8. Inhibition of platelet-derived growth factor (PDGF)-stimulated alone or with scrambled oligonucleotide, a significantcyclin D1 expression by ciglitazone. Mesangial cells were grown (50%
reduction in PPRE-driven luciferase activity was ob-confluence) in 60 mm dishes and made quiescent by 48 hours of serum
starvation. At the end of 48 hours, serum-free media was replaced with served in the presence of PPRE decoy (Fig. 10A).
0.5% serum-containing media and the cells were exposed to PDGF (20 To examine the effects of the PPRE decoy on mesan-
ng/mL) in presence or absence of 1, 10, and 20 mol/L of ciglitazone
gial cell proliferation, the cells were transiently transfected(Cig). Ciglitazone was added 4 hours prior to the addition of PDGF.
After 24 hours, the cells were lysed in ice and total proteins were with the PPRE decoy/scrambled oligonucleotide and stimu-
extracted. Total cell extracts (50 g protein) were separated by sodium lated with PDGF. The rationale for this experiment was
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in
that the decoy oligonucleotide would bind to the ligand8-16% gels. Cyclin D1 protein levels were analyzed by immunoblotting
using cyclin D1 antibody (1:5000). Actin was used as loading control. ciglitazone-activated PPAR and prevent PPAR-mediated
The autoradiogram at the top is representative of 5 experiments. Cyclin effects on gene transcription and proliferation. As shown
D1 expression was analyzed by scanning the autoradiograms. The ratio in Figure 10B, when the cells were transiently transfectedof cyclin D1 and actin was expressed as fold change from the control.
with PPRE decoy oligonucleotide, 10 mol/L of ciglita-The control value was considered to be 100%. The results are expressed
as mean  SD. *P  0.01 and ‡P  0.001 less than PDGF. zone had no effect on PDGF-induced proliferation. In
contrast, when cells were transfected with scrambled oli-
gonucleotide, 10 mol/L of ciglitazone significantly in-Down-regulation of p27 in response to mitogens (e.g.,
hibited (P  0.05) PDGF-stimulated proliferation (Fig.PDGF) is important for maximal activation of cyclin/
10B). As shown in Figure 10A, there is a 90% reductioncyclin D kinase holenzyme. We therefore investigated
in PPRE-mediated gene expression by decoy, which isthe effect of PPAR ligand ciglitazone on p27 protein
consistent with the effect of decoy oligonucleotide on cellexpression by Western blot analysis. Quiescent mesan-
proliferation. These observations indicate that ciglitazonegial cells revealed substantial p27 protein expression.
inhibits proliferation via PPAR.However, the expression of p27 was attenuated to 33 
6% of control (P  0.001) after 24 hours exposure of
Potentiating effect of ciglitazone and the MEKPDGF. The PDGF-mediated down-regulation of p27
inhibitor, PD98059was significantly reversed by ciglitazone. The expression
PD98059 is a specific inhibitor of ERK activation andof p27 was up-regulated to 56  7% (P  0.01), 98 
has been shown to reduce PDGF- induced ERK activa-17%, and 115  11% (P  0.001) of the control by 1,
tion in a dose-dependent fashion [27]. Our results dem-10, and 20 mol/L ciglitazone, respectively (Fig. 9A). In
onstrated attenuation of proliferation by ciglitazone andcontrast to p27, mitogens are known to up-regulate p21,
at a site(s) downstream of ERK activation. Thereforeand the expression of p21 protein is required for facilitat-
ing functional kinase complex formation of CDK4 and we extended these studies to investigate the combined
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Fig. 9. Effect of ciglitazone on platelet-
derived growth factor (PDGF)-mediated ex-
pression of p27 and p21. Mesangial cells were
grown (50% confluence) in 60 mm dishes
and made quiescent by 48 hours of serum star-
vation. Serum-free media was replaced with
0.5% serum-containing media after 48 hours
and the cells were exposed to PDGF (20 ng/
mL) in presence or absence of 1, 10, and 20
mol/L of ciglitazone (Cig). Ciglitazone was
added 4 hours prior to the addition of PDGF.
After 24 hours, the cells were scraped and
protein extracts (100 g protein for p21 and
50 g protein for p27) were separated by so-
dium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) in 8-16% gels. The
blots were analyzed by immunoblotting using
p21 antibody (see Fig. 8) and p27 antibody
(see Fig. 8). Actin was used as loading con-
trol. The ratio of p21 and actin (Fig. 8) and
p27 and actin were expressed as fold change
from the control. The control value was con-
sidered to be 100%. The results are expressed
as mean  SD.
effects of ciglitazone and PD98059 on PDGF-induced and inhibition of cell growth occurs by blocking the MAP
cell proliferation. Pretreatment of cells with threshold kinase pathway at a point downstream from extracellular
concentrations of PD98059 (2.5 mol/L) had no signifi- signal-regulated protein kinase (ERK) activation (Fig. 1).
cant effect on proliferation. However, the effect of these The ERK pathway is an integral part of the MAP kinase
inhibitors in combination was potentiating. As shown in pathway and is critical to the mitogenic response, cellular
Figure 11, PD989059 (2.5 mol/L) further potentiated differentiation, or hypertrophy. Antisense RNA and
the inhibitory effect of ciglitazone (1 and 10 mol/L) by dominant-negative mutant studies have clearly docu-
34  6% and 50  7%, respectively. Although PD98059
mented that ERK1/2 is essential for cell cycle progressionpotentiated the antiproliferative effect of ciglitazone
[28]. PDGF is responsible for the transduction of mito-(P 0.05), the decrease was 50 5% and the percent of
genic signals from the cell membrane to the nucleus,change was not significantly different from that observed
which involves a cascade of protein-binding events andwith 10 mol/L of ciglitazone. These results provide evi-
modifications, including a series of phosphorylation re-dence that inhibiting MAPK at proximal (by PD98059-
mediated inhibition of ERK activation) and distal sites sulting in the activation of MAP kinase pathway. In
(by ciglitazone-mediated effect on c-fos, cyclin, p21, and our study ciglitazone did not inhibit phosphorylation of
p27) can produce significantly higher antiproliferative ERK, a finding similar to the observation that Ang II-
response than targeting a single site. induced ERK activation could not be blocked by TZDs
[29]. The ability of ciglitazone alone to inhibit prolifera-
DISCUSSION tion indicates that ciglitazone inhibits MAP kinase distal
to ERK activation.The present investigation demonstrates that the anti-
proliferative effect of ciglitazone is mediated by PPAR The ability of PDGF to trigger cell cycle progression
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Fig. 10. Decoy oligonucleotide inhibits PPRE driven promoter activ-
ity. (A ) Mesangial cells cultured in 24-well plates were cotransfected
with a PPAR reporter vector and PPRE decoy oligonucleotide/scram-
bled oligonucleotide (400 nmol). The transfections were performed
Fig. 11. Combined treatment of ciglitazone and PD98059 synergisti-using Lipofectamine 2000. Twenty-four hours posttransfection, the cells
cally inhibits platelet-derived growth factor (PDGF)-induced mesangialwere stimulated with PDGF in the presence of 10 mol/L of ciglitazone
cell proliferation. Mesangial cells were grown to 50 confluence and(Cig). PPRE-driven luciferase activity was monitored and normalized
made quiescent by 48 hours of incubation in serum-free media. At theto Renilla luciferase. Results are expressed as mean  SD (N 
 4).
end of 48 hours, serum-free media was replaced with 0.5% serum-(B ) Mesangial cells cultured in 24-well plates were transfected with
containing media and the cells were exposed to PDGF (20 ng/mL) ineither 400 nmol of either decoy or scrambled oligonucleotides. The
absence or presence of ciglitazone (1, 10, and 20 mol/L) and PD98059transfections were performed using oligofectamine. Twenty-four hours
(2.5 mol/L). Cell proliferation was measured using Alamar Blue byposttransfection, the cells were made quiescent by serum withdrawal
spectrofluorometric method. Data shown are mean of 5 experimentsfor 48 hours and then stimulated with PDGF in the presence of ciglita-
done in duplicate. The results are expressed as mean  SD.zone (Cig). Data shown are the average of 4 experiments done in
duplicate. The results are expressed as mean SD. P 0.05 vs. PDGF-
stimulated proliferation.
response elements in the promoter region [14] and is
thus a potential target gene for AP-1 complexes. During
depends on c-fos and related transcription factors cell cycle, cyclin D, along with its catalytic partner, CDK,
[30, 31]. The cis acting serum response element (SRE) are induced by mitogenic signals. Cip/Kip proteins p21
is crucial for mitogen-induced c-fos transcription. Tran- and p27 control cell cycle progression by modulating
scriptional activation of the c-fos gene by PDGF is stimu- cyclin D and CDK binding [22, 23]. Increased expression
lated, at least in part, through the interaction of transcrip- of c-fos leads to activation of cyclin D1, a key mediator
tion factors with a SRE located in the c-fos 5-flanking in cell proliferation. Cyclin D1 protein regulates the cell
DNA [7, 8]. In our experiments we have shown ciglita- cycle by binding to CDK, thereby causing phosphoryla-
zone decreased SRE mediated gene expression. Since tion and inactivation of retinoblastoma tumor suppressor
SRE is responsible for transcriptional activation of c-fos, protein, which inhibits G1 to S phase transition. The
it was hypothesized that ciglitazone-mediated PPAR promoter for cyclin D1 contains an AP-1 site, and expres-
activation will decrease c-fos formation. Our results con- sion of either c-fos or c-jun induces cyclin D1 mRNA
firm the earlier observations of Law et al [32], who expression [10, 33]. Fibroblasts derived from fosB/
showed that the TZD analog troglitazone inhibits SRE c-fos/ mice were found to have a defect in prolifera-
function and reduces c-fos mRNA induction by basic tion that results, at least in part, from a failure to induce
FGF. cyclin D1 following serum-stimulated cell cycle reentry
[34]. Ciglitazone-mediated inhibition c-fos and de-C-fos and its heterodimeric partner c-jun (AP-1 com-
plex) promote cell proliferation by transactivation of creased cyclin D1 expression shown here can result in
the blockade of cell proliferation. Compared to SREcyclin D1, a key protein promoting the cell cycle [9].
Cyclin D1 gene has been shown to harbor two AP-1 and c-fos, equivalent molar concentrations of ciglitazone
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were more potent in inhibiting cyclin D1 formation, sug- inference, other studies have shown that TZDs play an
important role in cell cycle regulation via PPAR [11].gesting ciglitazone might affect other pathways responsi-
ble for the generation of cyclin. Since PPAR agonists Stimulation of the MAP kinase is sufficient to promote
cell proliferation [39]. Blockade of the ERK pathway bysuch as thiazolidinediones can cause substantial blockade
of retinoblastoma protein phosphorylation by attenuat- treatment with the MEK inhibitor, PD 98059, suppressed
the proliferation of both HT1080 and RPMI-SE tumoring degradation of CDK inhibitors [35], the role of cigli-
tazone on CDK inhibitors was evaluated. Although it is cell lines [40]. In our study PD 98059 significantly aug-
mented the antiproliferative effect of ciglitazone. Thisgenerally assumed that CDK inhibitors act solely to re-
tard G1 progression, the fact that they can be found in interaction between MEK inhibitor and ciglitazone
might have therapeutic implications since the combina-complexes with active cyclin CDKs raises the possibility
of that they may be positive regulators [22, 23]. In our tion of agents acting at different steps in the MAP kinase
signaling pathway might prove to be more effective thanexperiments PDGF induced the expression of CDK in-
hibitor p21, and this was blocked by ciglitazone. In- single agents in treating proliferative glomerular disease.
creased expression of p21 during proliferation is ob-
served because it acts as a scaffold to facilitate the
CONCLUSION
assembly of cyclins and CDKs required for DNA synthe-
We have demonstrated that the antiproliferative ac-sis [23]. It has been shown that PPAR agonist troglita-
tion of ciglitazone is mediated via PPAR. This inhibi-zone blocks glomerular cell proliferation and this effect
tion can be enhanced by simultaneous attenuation ofis associated with a decrease in p21 expression [14]. Re-
ERK phosphorylation by inhibition of pathways up-ducing the levels of p27 by transfecting mesangial cells
stream from ERK (e.g., MEK). Ciglitazone inhibits mes-with p27 antisense oligodeoxynucleotides results in an
angial cell proliferation by inhibiting SRE-mediatedincreased magnitude of mesangial cell proliferation in-
transcriptional activation of c-fos gene, resulting in de-duced by PDGF [36]. Our data shows that PDGF down-
creased c-fos and cyclin D1 protein expression. Althoughregulates p27 and the effect is reversed by ciglitazone.
our results further demonstrate that ciglitazone reversesTherefore up-regulation of p27 and down-regulation of
the effects of PDGF on p27 and p21 expression, the netp21 by ciglitazone can be a downstream mechanism by
result of these changes on CDK activity are currentlywhich PPAR agonist ciglitazone exerts its antiprolifera-
under investigation. Furthermore, the potentiating effecttive effect.
of ciglitazone and MEK inhibitor PD 98059 at relativelyAntiproliferative effects of TZDs are mediated via
lower concentrations on PDGF-induced cell prolifera-PPAR [11, 35]. However, there is a growing body of
tion suggest that a significantly higher antiproliferativeliterature which suggests that TZDs may produce their
effect can be achieved by combining two agents actingpharmacologic effect independent of PPAR [24–26]. In
at two different sites in the MAP kinase pathway.a recent study of mouse embryonic stem cells it has been
shown that the antiproliferative action of TZDs is the Reprint requests to Anton C. Schoolwerth, Division of Nephrology,
consequence of partial depletion of intracellular calcium MCV Campus, Virginia Commonwealth University, Box 980160, Rich-
mond, VA 23298.stores and not by PPAR [24]. To provide the evidence
E-mail: aschoolw@mail2.vcu.eduthat PPAR is required for the antiproliferative effect
of ciglitazone, we developed a double-stranded decoy
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